UroGen Pharma Ltd. Payments to Acquire Restricted Investments
UroGen Pharma Ltd. (URGN) reported Payments to Acquire Restricted Investments of $172.00 thousand for the 12-month period ending 2019-12-31, per its 10-K filed 2021-03-18.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireRestrictedInvestments · last filed 2021-03-18
- UroGen Pharma Ltd. payments to acquire restricted investments for the quarter ending 2019-12-31 was $168.00K.
- UroGen Pharma Ltd. payments to acquire restricted investments for the quarter ending 2019-09-30 was $0.00.
- UroGen Pharma Ltd. payments to acquire restricted investments for fiscal 2019 was $172.00K, a 218.52% increase from fiscal 2018.
- UroGen Pharma Ltd. payments to acquire restricted investments for fiscal 2018 was $54.00K, a 980.00% increase from fiscal 2017.
- UroGen Pharma Ltd. payments to acquire restricted investments for fiscal 2017 was $5.00K.
| Period end | Payments to Acquire Restricted Investments 3 month | Payments to Acquire Restricted Investments 6 month | Payments to Acquire Restricted Investments 9 month | Payments to Acquire Restricted Investments 12 month |
|---|---|---|---|---|
| 2019-12-31 | $168.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $168.00K derived: sum of 2 quarters · filed 2021-03-18 | $172.00K 10-K · filed 2021-03-18 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $4.00K 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $4.00K 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $54.00K 10-K · filed 2020-03-02 | |||
| 2017-12-31 | $5.00K 10-K · filed 2020-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |